CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ReShape Weightloss Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ReShape Weightloss Inc
1001 Calle Amanecer
Phone: (949) 429-6680p:949 429-6680 SAN CLEMENTE, CA  92673-6260  United States Fax: (651) 634-3212f:651 634-3212
This company was Merged or Acquired on 6/15/2021.
This company ceased filing statements with the SEC on 6/22/2021.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
ReShape Weightloss Inc., formerly ReShape Lifesciences Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company's initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company's VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202112/31/2020YesYes-YesYes

Industries
SIC Code Description
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Dan W.Gladney 66 3/31/2019 11/16/2015
President, Chief Executive Officer, Director Barton P.Bandy 58 5/8/2019 4/1/2019
Chief Financial Officer ThomasStankovich 58 10/30/2019 10/30/2019
4 additional Officers and Directors records available in full report.

Business Names
Business Name
BarioSurg, Inc.
EnteroMedics Inc.
ETRM
8 additional Business Names available in full report.

General Information
Number of Employees: 43 (As of 12/31/2018)
Outstanding Shares: 6,166,554 (As of 5/14/2021)
Shareholders: 19
Stock Exchange: OTC
Federal Tax Id: 481293684
Fax Number: (651) 634-3212


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 5, 2024